Here is the confusion most people run into: Ozempic and Wegovy contain the exact same active ingredient — semaglutide. They are both made by Novo Nordisk. They are both injected once weekly. Yet they are not interchangeable, and your doctor cannot simply swap one for the other on your insurance. The FDA approval, the approved dosing ceiling, the pen device, and the clinical indication are different for each.
This guide cuts through the marketing and explains exactly what each drug is approved for, what the clinical trials showed, who qualifies for each, what they cost, and how to actually access them in 2026.
| Feature | Ozempic | Wegovy |
|---|---|---|
| FDA Indication | Type 2 diabetes + cardiovascular risk reduction | Chronic weight management (obesity or overweight with comorbidity) |
| Active Ingredient | Semaglutide | Semaglutide |
| Maximum Dose | 2 mg/week | 2.4 mg/week |
| Pen Device | FlexTouch pen (0.25, 0.5, 1, 2 mg) | Separate injection pen (0.25 → 2.4 mg titration) |
| Dosing Schedule | Start 0.25 mg × 4 weeks → 0.5 mg → up to 2 mg | Start 0.25 mg × 4 weeks → titrate over 16 weeks to 2.4 mg |
| FDA Approval Year | 2017 (T2D) · 2021 (CV risk reduction) | 2021 (obesity/weight management) |
| Insurance Coverage | Usually covered with T2D diagnosis | Often excluded; Medicare Part D coverage expanded 2024 |
| Avg List Price/Month | ~$935 list; ~$25–100 with commercial insurance | ~$1,350 list; $0–650 with insurance/savings card |
| Novo Nordisk Savings Card | Yes (eligible commercially insured patients) | Yes — as low as $25/month for eligible patients |
| Key Clinical Trial | SUSTAIN program (SUSTAIN-6 for CV outcomes) | STEP program (STEP 1–5) |
The single most important distinction is the FDA-approved indication. This is not a technicality — it determines whether your insurance pays, what dose your doctor can prescribe, and what clinical evidence backs the use.
Ozempic was approved in December 2017 primarily to improve glycemic control in adults with type 2 diabetes. In 2021, its label was updated to include reducing the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease. Weight loss is a clinically significant side effect — but it is not the primary indication. If a doctor prescribes Ozempic to someone without type 2 diabetes purely for weight loss, that is an off-label use that most insurance plans will not cover.
Wegovy was approved in June 2021 specifically for chronic weight management in adults with a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with obesity or overweight and established cardiovascular disease — the first weight-loss drug ever approved for that indication. This approval was based on the SELECT trial, which showed a 20% reduction in major cardiovascular events vs. placebo.
In the SELECT trial (N=17,604 adults with obesity and established CVD but no diabetes), Wegovy reduced the risk of major adverse cardiovascular events by 20% vs. placebo over a median follow-up of 3.3 years. This was a landmark finding — the first time a GLP-1 agonist dosed for weight loss, not diabetes, showed a CV benefit. The FDA approved this expanded indication in March 2024.
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) program consisted of eight phase 3 trials examining semaglutide in adults with type 2 diabetes. Key findings:
N = 3,297 adults with type 2 diabetes at high cardiovascular risk. Semaglutide 0.5 mg or 1 mg weekly vs. placebo over 2 years.
The 2 mg dose approved later showed even greater glycemic and weight effects in the SUSTAIN FORTE trial, confirming a clear dose-response relationship.
The STEP (Semaglutide Treatment Effect in People with Obesity) program consisted of five phase 3 trials examining semaglutide 2.4 mg in adults without type 2 diabetes (or with it, in STEP 2). These trials established the weight-loss evidence base for Wegovy.
N = 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity, without diabetes. Semaglutide 2.4 mg weekly plus lifestyle intervention vs. placebo over 68 weeks.
N = 1,210 adults with type 2 diabetes and obesity. Semaglutide 2.4 mg vs. 1 mg vs. placebo over 68 weeks.
People with type 2 diabetes tend to lose less weight on GLP-1s than those without — a clinically important nuance for anyone choosing between these drugs.
Participants who achieved weight loss on semaglutide 2.4 mg were randomized to continue or switch to placebo. Those who switched regained approximately two-thirds of their lost weight within one year. Conclusion: this is a chronic treatment, not a short-term fix. Both Ozempic and Wegovy require ongoing use to maintain their effects.
A person with type 2 diabetes and obesity technically qualifies for both drugs. In practice, doctors prescribe Ozempic when glycemic control is the priority and insurance covers it cleanly. They prescribe Wegovy when the patient's primary concern is weight and the insurance benefit covers it. In 2026, some commercial plans and Medicare Part D now cover Wegovy for the cardiovascular indication — check your specific plan formulary before assuming denial.
Because Ozempic and Wegovy contain the same molecule, their side effect profiles are nearly identical. Frequency and severity may be slightly higher at the 2.4 mg Wegovy dose during titration, but the categories of side effects are the same for both drugs.
This is not a complete side effect list. Discuss your full medical history with a licensed prescriber before starting either medication.
The list price for Ozempic is approximately $935 per month, but most commercially insured patients with type 2 diabetes pay significantly less — often $25–$100/month with coverage. Medicare Part D covers Ozempic for T2D. Novo Nordisk savings cards can reduce out-of-pocket cost to as low as $25/month for eligible commercially insured patients (not available for Medicare or Medicaid beneficiaries).
Wegovy's list price is approximately $1,349 per month. Insurance coverage is more variable. Many commercial plans now cover it, particularly since the 2024 cardiovascular indication expanded the eligible population. Medicare Part D was authorized to cover Wegovy for the CV indication under Inflation Reduction Act implementation, though specific plan coverage varies by formulary. Novo Nordisk's Wegovy savings card can bring cost to as low as $25/month for eligible commercially insured patients.
If your insurance denies Wegovy for weight management, check whether you have an established cardiovascular disease diagnosis (prior heart attack, stroke, or peripheral arterial disease). The 2024 SELECT trial approval gives physicians a stronger clinical argument for prior authorization appeals. Many denials are reversed on appeal with the right documentation and a letter of medical necessity from your prescriber citing the cardiovascular indication.
As of 2026, both Ozempic and Wegovy are accessible through telehealth platforms — though each platform has its own prescribing criteria and formulary preferences. The major players in the GLP-1 telehealth space include Hims & Hers, Ro, Noom Med, Calibrate, and Found, among others.
Most telehealth platforms prescribe Wegovy for weight management rather than Ozempic off-label, because the indication aligns with what patients present with (obesity or overweight) rather than diabetes. Some platforms also offer compounded semaglutide — a lower-cost alternative using pharmacy-compounded versions — though Novo Nordisk has contested availability as brand shortages resolve. See our Compounded vs Brand guide for the full picture on that option.
For a full breakdown of the best telehealth providers for GLP-1 medications in 2026 — including which accept insurance, which offer compounded options, and which have the most transparent pricing — see our GLP-1 Telehealth Provider Guide.
A clinically grounded guide to the GLP-1 drug class — covering mechanism of action, trial evidence, side effect management, and what to expect from long-term treatment. Useful for patients navigating their first prescription and for anyone trying to understand the science before starting.
View on Amazon →Affiliate link — we may earn a commission at no cost to you. See our disclosure.
You have type 2 diabetes and want better blood sugar control with incidental weight loss → Ozempic. It has strong CV outcome data in diabetic populations, better and more consistent insurance coverage, and a well-established prescribing track record since 2017.
You have obesity or overweight (with a comorbidity) and weight loss is your primary goal → Wegovy. The 2.4 mg dose ceiling produces greater average weight loss, and the indication is purpose-built for chronic weight management. The 2024 SELECT trial data gives Wegovy a cardiovascular outcomes label of its own, now covering a broader population beyond diabetic patients.
You have both type 2 diabetes and obesity and want maximum weight loss → discuss Wegovy with your doctor. The STEP 2 trial tested Wegovy 2.4 mg in diabetic patients and showed both weight loss and glycemic improvement, though weight loss was less pronounced (~9.6% vs. ~14.9% in non-diabetic patients).
The molecular difference is 0.4 mg. The clinical difference is the indication, the device, the approval history, and how your insurance processes the claim. Neither drug is inherently superior — the right one is the one your physician prescribes for your specific diagnosis and that your insurance will actually cover. Start that conversation with a board-certified prescriber, not a social media post.
Yes. Wegovy is approved regardless of diabetes status. Patients with type 2 diabetes who take Wegovy typically see improvements in both weight and blood sugar. Your prescriber may adjust or discontinue other diabetes medications as glycemic control improves.
Technically yes — off-label prescribing is legal in the US. But your insurance almost certainly will not cover it for that indication, and you would pay the full list price of approximately $935/month. Wegovy is the appropriate on-label choice for weight management without a diabetes diagnosis.
The STEP 4 withdrawal trial showed that participants who stopped semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year. Both drugs require ongoing treatment to maintain effects. This mirrors how other chronic conditions — hypertension, high cholesterol — are managed: the treatment needs to continue for the benefit to persist.
No meaningful safety difference exists between the two, since they contain the same molecule. The slightly higher dose of Wegovy (2.4 mg vs. 2 mg maximum for Ozempic) may produce slightly higher rates of GI side effects during titration, but this has not translated into a meaningfully different overall safety profile in clinical trial data.
Compounded semaglutide contains the same active ingredient but is not FDA-approved and is not manufactured under the same quality controls as brand-name products. During shortage periods, the FDA permitted compounding pharmacies to produce semaglutide. As of mid-2026, Novo Nordisk has asserted supply is normalized and the FDA has restricted new compounding. See our Compounded vs Brand guide for the full current picture.